DNA Damage-driven Inflammatory Cytokines: Reprogramming of Tumor Immune Microenvironment and Application of Oncotherapy

Abstract

DNA damage occurs across tumorigenesis and tumor development. Tumor intrinsic DNA damage can not only increase the risk of mutations responsible for tumor generation but also initiate a cellular stress response to orchestrate the tumor immune microenvironment (TIME) and dominate tumor progression. Accumulating evidence documents that multiple signaling pathways, including cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) and ataxia telangiectasia-mutated protein/ataxia telangiectasia and Rad3-related protein (ATM/ATR), are activated downstream of DNA damage and they are associated with the secretion of diverse cytokines. These cytokines possess multifaced functions in the anti-tumor immune response. Thus, it is necessary to deeply interpret the complex TIME reshaped by damaged DNA and tumor-derived cytokines, critical for the development of effective tumor therapies. This manuscript comprehensively reviews the relationship between the DNA damage response and related cytokines in tumors and depicts the dual immunoregulatory roles of these cytokines. We also summarize clinical trials targeting signaling pathways and cytokines associated with DNA damage and provide future perspectives on emerging technologies.

Keywords

DNA damage / tumor immune microenvironment / inflammatory cytokines / cancer therapy

References

[1]	Bonapace L, Coissieux MM, Wyckoff J, et al. Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis. Nature, 2014,515(7525):130–133
[2]	M K PK, Shyama SK, D’Costa A, et al. Evaluation of DNA damage induced by gamma radiation in gill and muscle tissues of Cyprinus carpio and their relative sensitivity. Ecotoxicol Environ Saf, 2017,144:166–170
[3]	Fu D, Calvo JA, Samson LD. Balancing repair and tolerance of DNA damage caused by alkylating agents. Nat Rev Cancer, 2012,12(2):104–120
[4]	Xiaofei E, Kowalik TF. The DNA damage response induced by infection with human cytomegalovirus and other viruses. Viruses, 2014,6(5):2155–2185
[5]	Papamichos-Chronakis M, Peterson CL. Chromatin and the genome integrity network. Nat Rev Genet, 2013,14(1):62–75
[6]	Romei C, Elisei R. A Narrative Review of Genetic Alterations in Primary Thyroid Epithelial Cancer. Int J Mol Sci, 2021,22(4):1726
[7]	Marti TM, Fleck O. DNA repair nucleases. Cell Mol Life Sci, 2004,61(3):336–354
[8]	Greten FR, Grivennikov SI. Inflammation and Cancer: Triggers, Mechanisms, and Consequences. Immunity, 2019,51(1):27–41
[9]	Salem ML, Attia ZI, Galal SM. Acute inflammation induces immunomodulatory effects on myeloid cells associated with anti-tumor responses in a tumor mouse model. J Adv Res, 2016,7(2):243–253
[10]	Al-Kadhimi Z, Callahan M, Fehniger T, et al. Enrichment of innate immune cells from PBMC followed by triple cytokine activation for adoptive immunotherapy. Int Immunopharmacol, 2022,113(Pt A):109387
[11]	Ben-Baruch A. Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators. Semin Cancer Biol, 2006,16(1):38–52
[12]	Kundu JK, Surh YJ. Inflammation: gearing the journey to cancer. Mutat Res, 2008,659(1–2):15–30
[13]	Cai W, Kerner ZJ, Hong H, et al. Targeted Cancer Therapy with Tumor Necrosis Factor-Alpha. Biochem Insights, 2008,2008:15–21
[14]	Guo Y, Xu F, Lu T, et al. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev, 2012,38(7):904–910
[15]	Neuzillet C, Tijeras-Raballand A, Cohen R, et al. Targeting the TGFβ pathway for cancer therapy. Pharmacol Ther, 2015,147:22–31
[16]	Wei J, Ma L, Lai YH, et al. Bazedoxifene as a novel GP130 inhibitor for Colon Cancer therapy. J Exp Clin Cancer Res, 2019,38(1):63
[17]	Macheret M, Halazonetis TD. DNA replication stress as a hallmark of cancer. Annu Rev Pathol, 2015,10:425–448
[18]	Negrini S, Gorgoulis VG, Halazonetis TD. Genomic instability—an evolving hallmark of cancer. Nat Rev Mol Cell Biol, 2010,11(3):220–228
[19]	Bhat AA, Nisar S, Singh M, et al. Cytokine- and chemokine-induced inflammatory colorectal tumor microenvironment: Emerging avenue for targeted therapy. Cancer Commun (Lond), 2022,42(8):689–715
[20]	Hamperl S, Bocek MJ, Saldivar JC, et al. Transcription-Replication Conflict Orientation Modulates R-Loop Levels and Activates Distinct DNA Damage Responses. Cell, 2017,170(4):774–786
[21]	Kato K, Omura H, Ishitani R, et al. Cyclic GMP-AMP as an Endogenous Second Messenger in Innate Immune Signaling by Cytosolic DNA. Annu Rev Biochem, 2017,86:541–566
[22]	Gao P, Ascano M, Wu Y, et al. Cyclic [G(2’,5’)pA(3’,5’) p] is the metazoan second messenger produced by DNA-activated cyclic GMP-AMP synthase. Cell, 2013,153(5):1094–1107
[23]	Ishikawa H, Barber GN. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature, 2008,455(7213):674–678
[24]	Zhang C, Shang G, Gui X, et al. Structural basis of STING binding with and phosphorylation by TBK1. Nature, 2019,567(7748):394–398
[25]	Tanaka Y, Chen ZJ. STING specifies IRF3 phosphorylation by TBK1 in the cytosolic DNA signaling pathway. Sci Signal, 2012,5(214):ra20
[26]	Yang C, Bachu M, Du Y, et al. CXCL4 synergizes with TLR8 for TBK1-IRF5 activation, epigenomic remodeling and inflammatory response in human monocytes. Nat Commun, 2022,13(1):3426
[27]	Yu N, Xu X, Qi G, et al. Ctenopharyngodon idella TBK1 activates innate immune response via IRF7. Fish Shellfish Immunol, 2018,80:521–527
[28]	Li X, Song D, Chen Y, et al. NSD2 methylates AROS to promote SIRT1 activation and regulates fatty acid metabolism-mediated cancer radiotherapy. Cell Rep, 2023,42(10):113–126
[29]	Tao J, Zhou X, Jiang Z. cGAS-cGAMP-STING: The three musketeers of cytosolic DNA sensing and signaling. IUBMB life, 2016,68(11):858–870
[30]	Guo Q, Chen X, Chen J, et al. STING promotes senescence, apoptosis, and extracellular matrix degradation in osteoarthritis via the NF-κB signaling pathway. Cell Death Dis, 2021,12(1):13
[31]	Bonizzi G, Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol, 2004,25(6):280–288
[32]	Sun SC. Non-canonical NF-κB signaling pathway. Cell Res, 2011,21(1):71–85
[33]	Gilmore TD. Introduction to NF-kappaB: players, pathways, perspectives. Oncogene, 2006,25(51):6680–6684
[34]	Kang C, Xu Q, Martin TD, et al. The DNA damage response induces inflammation and senescence by inhibiting autophagy of GATA4. Science, 2015,349(6255):aaa5612
[35]	Qiao W, Huang Y, Bian Z, et al. Lipopolysaccharide-induced DNA damage response activates nuclear factor κB signalling pathway via GATA4 in dental pulp cells. Int Endod J, 2019,52(12):1704–1715
[36]	Hinz M, Stilmann M, Arslan S ?, et al. A cytoplasmic ATM-TRAF6-cIAP1 module links nuclear DNA damage signaling to ubiquitin-mediated NF-κB activation. Mol Cell, 2010,40(1):63–74
[37]	Fang L, Choudhary S, Zhao Y, et al. ATM regulates NF-κB-dependent immediate-early genes via RelA Ser 276 phosphorylation coupled to CDK9 promoter recruitment. Nucleic Acids Res, 2014,42(13):8416–8432
[38]	Zhao M, Wang Y, Li L, et al. Mitochondrial ROS promote mitochondrial dysfunction and inflammation in ischemic acute kidney injury by disrupting TFAM-mediated mtDNA maintenance. Theranostics, 2021,11(4):1845–1863
[39]	Shafman T, Khanna KK, Kedar P, et al. Interaction between ATM protein and c-Abl in response to DNA damage. Nature, 1997,387(6632):520–523
[40]	Liu X, Rong F, Tang J, et al. Repression of p53 function by SIRT5-mediated desuccinylation at Lysine 120 in response to DNA damage. Cell Death Differ, 2022,29(4):722–736
[41]	Tengesdal IW, Dinarello A, Powers NE, et al. Tumor NLRP3-Derived IL-1β Drives the IL-6/STAT3 Axis Resulting in Sustained MDSC-Mediated Immunosuppression. Front Immunol, 2021,12:661323
[42]	Mantovani A, Dinarello CA, Molgora M, et al. Interleukin-1 and Related Cytokines in the Regulation of Inflammation and Immunity. Immunity, 2019,50(4):778–795
[43]	Fahey E, Doyle SL. IL-1 Family Cytokine Regulation of Vascular Permeability and Angiogenesis. Front Immunol, 2019,10:1426
[44]	Xu C, Xia Y, Zhang BW, et al. Macrophages facilitate tumor cell PD-L1 expression via an IL-1β-centered loop to attenuate immune checkpoint blockade. MedComm (2020), 2023,4(2):e242
[45]	Dammeijer F, van Gulijk M, Mulder EE, et al. The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes. Cancer Cell, 2020,38(5):685–700
[46]	Xu Y, Song G, Xie S, et al. The roles of PD-1/PD-L1 in the prognosis and immunotherapy of prostate cancer. Mol Ther, 2021,29(6):1958–1969
[47]	Rose John S, Schooltink H. Cytokines are a therapeutic target for the prevention of inflammation-induced cancers. Recent Results Cancer Res, 2007,174:57–66
[48]	Bromberg JF, Wrzeszczynska MH, Devgan G, et al. Stat3 as an oncogene. Cell, 1999,98(3):295–303
[49]	Johnson DE, O’Keefe RA, Grandis JR. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol, 2018,15(4):234–248
[50]	Matsui T, Kinoshita T, Hirano T, et al. STAT3 down-regulates the expression of cyclin D during liver development. J Biol Chem, 2002,277(39):36167–36173
[51]	Yar Saglam AS, Alp E, Elmazoglu Z, et al. Treatment with cucurbitacin B alone and in combination with gefitinib induces cell cycle inhibition and apoptosis via EGFR and JAK/STAT pathway in human colorectal cancer cell lines. Hum Exp Toxicol, 2016,35(5):526–543
[52]	Jones SA, Jenkins BJ. Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nat Rev Immunol, 2018,18(12):773–789
[53]	Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol, 2014,6(10):a016295
[54]	Li D, Xie K, Zhang L, et al. Dual blockade of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (FGF-2) exhibits potent anti-angiogenic effects. Cancer Lett, 2016,377(2):164–173
[55]	Dong C. TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat Rev Immunol, 2008,8(5):337–348
[56]	Weber R, Riester Z, Hüser L, et al. IL-6 regulates CCR5 expression and immunosuppressive capacity of MDSC in murine melanoma. J Immunother Cancer, 2020,8(2):e000949
[57]	Magidey-Klein K, Cooper TJ, Kveler K, et al. IL-6 contributes to metastatic switch via the differentiation of monocytic-dendritic progenitors into prometastatic immune cells. J Immunother Cancer, 2021,9(6):e002856
[58]	iang Z, Liao R, Lv J, et al. IL-6 trans-signaling promotes the expansion and anti-tumor activity of CAR T cells. Leukemia, 2021,35(5):1380–1391
[59]	Qian BZ, Li J, Zhang H, et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature, 2011,475(7355):222–225
[60]	Yang Z, Li H, Wang W, et al. CCL2/CCR2 Axis Promotes the Progression of Salivary Adenoid Cystic Carcinoma via Recruiting and Reprogramming the Tumor-Associated Macrophages. Front Oncol, 2019,9:231
[61]	Yang H, Zhang Q, Xu M, et al. CCL2-CCR2 axis recruits tumor associated macrophages to induce immune evasion through PD-1 signaling in esophageal carcinogenesis. Mol Cancer, 2020,19(1):41
[62]	Flores-Toro JA, Luo D, Gopinath A, et al. CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas. Proc Natl Acad Sci U S A, 2020,117(2):1129–1138
[63]	Epstein RJ. The CXCL12-CXCR4 chemotactic pathway as a target of adjuvant breast cancer therapies. Nat Rev Cancer, 2004,4(11):901–909
[64]	Heidegger I, Fotakis G, Offermann A, et al. Comprehensive characterization of the prostate tumor microenvironment identifies CXCR4/CXCL12 crosstalk as a novel antiangiogenic therapeutic target in prostate cancer. Mol Cancer, 2022,21(1):132
[65]	Wald O, Shapira OM, Izhar U. CXCR4/CXCL12 axis in non small cell lung cancer (NSCLC) pathologic roles and therapeutic potential. Theranostics, 2013,3(1):26–33
[66]	Song ZY, Gao ZH, Chu JH, et al. Downregulation of the CXCR4/CXCL12 axis blocks the activation of the Wnt/β-catenin pathway in human colon cancer cells. Biomed Pharmacother, 2015,71:46–52
[67]	Yin X, Liu Z, Zhu P, et al. CXCL12/CXCR4 promotes proliferation, migration, and invasion of adamantinomatous craniopharyngiomas via PI3K/AKT signal pathway. J Cell Biochem, 2019,120(6):9724–9736
[68]	Zhou W, Guo S, Liu M, et al. Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy. Curr Med Chem, 2019,26(17):3026–3041
[69]	Ziegler ME, Hatch MMS, Wu N, et al. mTORC2 mediates CXCL12-induced angiogenesis. Angiogenesis, 2016,19(3):359–371
[70]	Liang Z, Brooks J, Willard M, et al. CXCR4/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathway. Biochem Biophys Res Commun, 2007,359(3):716–722
[71]	Lecavalier-Barsoum M, Chaudary N, Han K, et al. Targeting CXCL12/CXCR4 and myeloid cells to improve the therapeutic ratio in patient-derived cervical cancer models treated with radio-chemotherapy. Br J Cancer, 2019,121(3):249–256
[72]	Pan J, Mestas J, Burdick MD, et al. Stromal derived factor-1 (SDF-1/CXCL12) and CXCR4 in renal cell carcinoma metastasis. Mol Cancer, 2006,5:56
[73]	Taki M, Abiko K, Baba T, et al. Snail promotes ovarian cancer progression by recruiting myeloid-derived suppressor cells via CXCR2 ligand upregulation. Nat Commun, 2018,9(1):1685
[74]	Garg B, Giri B, Modi S, et al. NFκB in Pancreatic Stellate Cells Reduces Infiltration of Tumors by Cytotoxic T Cells and Killing of Cancer Cells, via Up-regulation of CXCL12. Gastroenterology, 2018,155(3):880–891
[75]	Kohara H, Omatsu Y, Sugiyama T, et al. Development of plasmacytoid dendritic cells in bone marrow stromal cell niches requires CXCL12-CXCR4 chemokine signaling. Blood, 2007,110(13):4153–4160
[76]	de Rham C, Ferrari-Lacraz S, Jendly S, et al. The proinflammatory cytokines IL-2, IL-15 and IL-21 modulate the repertoire of mature human natural killer cell receptors. Arthritis Res Ther, 2007,9(6):R125
[77]	Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol, 2003,3(2):133–146
[78]	Renavikar PS, Sinha S, Brate AA, et al. IL-12-Induced Immune Suppressive Deficit During CD8+ T-Cell Differentiation. Front Immunol, 2020,11:568630
[79]	Schurich A, Raine C, Morris V, et al. The role of IL-12/23 in T cell-related chronic inflammation: implications of immunodeficiency and therapeutic blockade. Rheumatology (Oxford), 2018,57(2):246–254
[80]	Garris CS, Arlauckas SP, Kohler RH, et al. Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12. Immunity, 2018,49(6):1148–1161
[81]	Albini A, Brigati C, Ventura A, et al. Angiostatin anti-angiogenesis requires IL-12: the innate immune system as a key target. J Transl Med, 2009,7:5
[82]	Abdolvahab MH, Darvishi B, Zarei M, et al. Interferons: role in cancer therapy. Immunotherapy, 2020,12(11):833–855
[83]	Musella M, Guarracino A, Manduca N, et al. Type I IFNs promote cancer cell stemness by triggering the epigenetic regulator KDM1B. Nat Immunol, 2022,23(9):1379–1392
[84]	Müller L, Aigner P, Stoiber D. Type I Interferons and Natural Killer Cell Regulation in Cancer. Front Immunol, 2017,8:304
[85]	Jiang W, Zhang C, Tian Z, et al. hIFN-α gene modification augments human natural killer cell line anti-human hepatocellular carcinoma function. Gene Ther, 2013,20(11):1062–1069
[86]	Hervas-Stubbs S, Perez-Gracia JL, Rouzaut A, et al. Direct effects of type I interferons on cells of the immune system. Clin Cancer Res, 2011,17(9):2619–2627
[87]	Olalekan SA, Cao Y, Hamel KM, et al. B cells expressing IFN-γ suppress Treg-cell differentiation and promote autoimmune experimental arthritis. Eur J Immunol, 2015,45(4):988–998
[88]	Sisirak V, Faget J, Gobert M, et al. Impaired IFN-α production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression. Cancer Res, 2012,72(20):5188–5197
[89]	Chen J, Cao Y, Markelc B, et al. Type I IFN protects cancer cells from CD8+ T cell-mediated cytotoxicity after radiation. J Clin Invest, 2019,129(10):4224–4238
[90]	Cheng N, Watkins-Schulz R, Junkins RD, et al. A nanoparticle-incorporated STING activator enhances antitumor immunity in PD-L1-insensitive models of triple-negative breast cancer. JCI Insight, 2018,3(22):e120638
[91]	Yadav MC, Burudi EME, Alirezaei M, et al. IFN-gamma-induced IDO and WRS expression in microglia is differentially regulated by IL-4. Glia, 2007,55(13):1385–1396
[92]	Pinci F, Gaidt MM, Jung C, et al. Tumor necrosis factor is a necroptosis-associated alarmin. Front Immunol, 2022,13:1074440
[93]	Nooijen PT, Manusama ER, Eggermont AM, et al. Synergistic effects of TNF-alpha and melphalan in an isolated limb perfusion model of rat sarcoma: a histopathological, immunohistochemical and electron microscopical study. Br J Cancer, 1996,74(12):1908–1915
[94]	van der Veen AH, de Wilt JH, Eggermont AM, et al. TNF-alpha augments intratumoural concentrations of doxorubicin in TNF-alpha-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects. Br J Cancer, 2000,82(4):973–980
[95]	Spriggs D, Imamura K, Rodriguez C, et al. Induction of tumor necrosis factor expression and resistance in a human breast tumor cell line. Proc Natl Acad Sci U S A, 1987,84(18):6563–6566
[96]	Karayiannakis AJ, Syrigos KN, Polychronidis A, et al. Serum levels of tumor necrosis factor-alpha and nutritional status in pancreatic cancer patients. Anticancer Res, 2001,21(2B):1355–1358
[97]	Moore RJ, Owens DM, Stamp G, et al. Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat Med, 1999,5(7):828–831
[98]	Naylor MS, Malik ST, Stamp GW, et al. In situ detection of tumour necrosis factor in human ovarian cancer specimens. Eur J Cancer, 1990,26(10):1027–1030
[99]	Cruceriu D, Baldasici O, Balacescu O, et al. The dual role of tumor necrosis factor-alpha (TNF-α) in breast cancer: molecular insights and therapeutic approaches. Cell Oncol (Dordr), 2020,43(1):1–18
[100]	Schr?der SK, Asimakopoulou A, Tillmann S, et al. TNF-α controls Lipocalin-2 expression in PC-3 prostate cancer cells. Cytokine, 2020,135:155214
[101]	Zhang GP, Yue X, Li SQ. Cathepsin C Interacts with TNF-α/p38 MAPK Signaling Pathway to Promote Proliferation and Metastasis in Hepatocellular Carcinoma. Cancer Res Treat, 2020,52(1):10–23
[102]	Liu Y, Gao Y, Lin T. Expression of interleukin-1 (IL-1), IL-6, and tumor necrosis factor-α (TNF-α) in non-small cell lung cancer and its relationship with the occurrence and prognosis of cancer pain. Ann Palliat Med, 2021,10(12):12759–12766
[103]	Edamitsu S, Matsukawa A, Ohkawara S, et al. Role of TNF alpha, IL-1, and IL-1ra in the mediation of leukocyte infiltration and increased vascular permeability in rabbits with LPS-induced pleurisy. Clin Immunol Immunopathol, 1995,75(1):68–74
[104]	Watanabe Y, Fukuda T, Hayashi C, et al. Extracellular vesicles derived from GMSCs stimulated with TNF-α and IFN-α promote M2 macrophage polarization via enhanced CD73 and CD5L expression. Sci Rep, 2022,12(1):13344
[105]	Kulbe H, Thompson R, Wilson JL, et al. The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. Cancer Res, 2007,67(2):585–592
[106]	Gordon G J, Mani M, Mukhopadhyay L, et al. Inhibitor of apoptosis proteins are regulated by tumour necrosis factor-alpha in malignant pleural mesothelioma. J Pathol, 2007,211(4):439–446
[107]	Stathopoulos GT, Kollintza A, Moschos C, et al. Tumor necrosis factor-alpha promotes malignant pleural effusion. Cancer Res, 2007,67(20):9825–9834
[108]	Lang FM, Lee KMC, Teijaro JR, et al. GM-CSF-based treatments in COVID-19: reconciling opposing therapeutic approaches. Nat Rev Immunol, 2020,20(8):507–514
[109]	Zhan Y, Lew AM, Chopin M. The Pleiotropic Effects of the GM-CSF Rheostat on Myeloid Cell Differentiation and Function: More Than a Numbers Game. Front Immunol, 2019,10:2679
[110]	Rosales C. Neutrophil: A Cell with Many Roles in Inflammation or Several Cell Types? Front Physiol, 2018,9:113
[111]	Celebi H, Akan H, Ak?a?layan E, et al. Febrile neutropenia in allogeneic and autologous peripheral blood stem cell transplantation and conventional chemotherapy for malignancies. Bone Marrow Transplant, 2000,26(2):211–214
[112]	Lemieux B, Tartas S, Traulle C, et al. Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin’s lymphoma. Bone Marrow Transplant, 2004,33(9):921–923
[113]	Ribechini E, Hutchinson JA, Hergovits S, et al. Novel GM-CSF signals via IFN-γR/IRF-1 and AKT/mTOR license monocytes for suppressor function. Blood Adv, 2017,1(14):947–960
[114]	Morales JK, Kmieciak M, Knutson KL, et al. GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1- bone marrow progenitor cells into myeloid-derived suppressor cells. Breast Cancer Res Treat, 2010,123(1):39–49
[115]	Comunanza V, Gigliotti C, Lamba S, et al. Dual VEGFA/BRAF targeting boosts PD-1 blockade in melanoma through GM-CSF-mediated infiltration of M1 macrophages. Mol Oncol, 2023,17(8):1474–1491
[116]	Van Overmeire E, Stijlemans B, Heymann F, et al. M-CSF and GM-CSF Receptor Signaling Differentially Regulate Monocyte Maturation and Macrophage Polarization in the Tumor Microenvironment. Cancer Res, 2016,76(1):35–42
[117]	Owen JL, Torroella-Kouri M, Handel-Fernandez ME, et al. GM-CSF up-regulates the expression of CCL2 by T lymphocytes in mammary tumor-bearing mice. Int J Mol Med, 2007,20(1):129–136
[118]	Sierra-Filardi E, Nieto C, Domínguez-Soto A, et al. CCL2 shapes macrophage polarization by GM-CSF and M-CSF: identification of CCL2/CCR2-dependent gene expression profile. J Immunol, 2014,192(8):3858–3867
[119]	Bhattacharya P, Gopisetty A, Ganesh BB, et al. GM-CSF-induced, bone-marrow-derived dendritic cells can expand natural Tregs and induce adaptive Tregs by different mechanisms. J Leukoc Biol, 2011,89(2):235–249
[120]	Arnold IC, Artola-Boran M, Gurtner A, et al. The GM-CSF-IRF5 signaling axis in eosinophils promotes antitumor immunity through activation of type 1 T cell responses. J Exp Med, 2020,217(12):e20190706
[121]	Kalinski P. Regulation of immune responses by prostaglandin E2. J Immunol, 2012,188(1):21–28
[122]	Dou Z, Ghosh K, Vizioli MG, et al. Cytoplasmic chromatin triggers inflammation in senescence and cancer. Nature, 2017,550(7676):402–406
[123]	Curran E, Chen X, Corrales L, et al. STING Pathway Activation Stimulates Potent Immunity against Acute Myeloid Leukemia. Cell Rep, 2016,15(11):2357–2366
[124]	Woo SR, Fuertes MB, Corrales L, et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity, 2014,41(5):830–842
[125]	Gajewski TF, Corrales L. New perspectives on type I IFNs in cancer. Cytokine Growth Factor Rev, 2015,26(2):175–178
[126]	Ahn J, Konno H, Barber GN. Diverse roles of STING-dependent signaling on the development of cancer. Oncogene, 2015,34(41):5302–5308
[127]	Xu N, Palmer DC, Robeson AC, et al. STING agonist promotes CAR T cell trafficking and persistence in breast cancer. J Exp Med, 2021,218(2):e20200844
[128]	Chen Q, Boire A, Jin X, et al. Carcinoma-astrocyte gap junctions promote brain metastasis by cGAMP transfer. Nature, 2016,533(7604):493–498
[129]	Lemos H, Mohamed E, Huang L, et al. STING Promotes the Growth of Tumors Characterized by Low Antigenicity via IDO Activation. Cancer Res, 2016,76(8):2076–2081
[130]	Ding L, Huang XF, Dong GJ, et al. Activated STING enhances Tregs infiltration in the HPV-related carcinogenesis of tongue squamous cells via the c-jun/CCL22 signal. Biochim Biophys Acta, 2015,1852(11):2494–2503
[131]	Kumar S, Nandi A, Singh S, et al. Dll1+ quiescent tumor stem cells drive chemoresistance in breast cancer through NF-κB survival pathway. Nat Commun, 2021,12(1):432
[132]	Somani VK, Zhang D, Dodhiawala PB, et al. IRAK4 Signaling Drives Resistance to Checkpoint Immunotherapy in Pancreatic Ductal Adenocarcinoma. Gastroenterology, 2022,162(7):2047–2062
[133]	Gresser I, Bourali C. Antitumor effects of interferon preparations in mice. J Natl Cancer Inst, 1970,45(2):365–376
[134]	Golomb HM, Jacobs A, Fefer A, et al. Alpha-2 interferon therapy of hairy-cell leukemia: a multicenter study of 64 patients. J Clin Oncol, 1986,4(6):900–905
[135]	Solal-Celigny P, Lepage E, Brousse N, et al. Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d’Etude des Lymphomes de l’Adulte. N Engl J Med, 1993,329(22):1608–1614
[136]	Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol, 1999,17(7):2105–2116
[137]	Groopman JE, Gottlieb MS, Goodman J, et al. Recombinant alpha-2 interferon therapy for Kaposi’s sarcoma associated with the acquired immunodeficiency syndrome. Ann Intern Med, 1984,100(5):671–676
[138]	Majer M, Welberg LAM, Capuron L, et al. IFN-alpha-induced motor slowing is associated with increased depression and fatigue in patients with chronic hepatitis C. Brain Behav Immun, 2008,22(6):870–880
[139]	Fioravanti J, González I, Medina-Echeverz J, et al. Anchoring interferon alpha to apolipoprotein A-I reduces hematological toxicity while enhancing immunostimulatory properties. Hepatology, 2011,53(6):1864–1873
[140]	Keilholz U, Goey SH, Punt CJ, et al. Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. J Clin Oncol, 1997,15(7):2579–2588
[141]	Rizza P, Capone I, Moretti F, et al. IFN-α as a vaccine adjuvant: recent insights into the mechanisms and perspectives for its clinical use. Expert Rev Vaccines, 2011,10(4):487–498
[142]	Groenewegen G, Bloem A, De Gast GC. PhaseI/II study of study of sequential chemoimmunotherapy (SCIT) for metastatic metastatic melanoma: outpatient treatment with dacarbazine, dacarbazine, granulocyte-macrophage colony-stimulating factor, low-dose interleukin-2, and interferon-alpha. Cancer Immunol Immunother, 2002,51(11–12):630–636
[143]	Di Pucchio T, Pilla L, Capone I, et al. Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors. Cancer Res, 2006,66(9):4943–4951
[144]	Brown ER, Charles KA, Hoare SA, et al. A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer. Ann Oncol, 2008,19(7):1340–1346
[145]	Harrison ML, Obermueller E, Maisey NR, et al. Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose. J Clin Oncol, 2007,25(29):4542–4549
[146]	Montfort A, Filleron T, Virazels M, et al. Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase Ib Clinical Trial. Clin Cancer Res, 2021,27(4):1037–1047
[147]	Deng L, Liang H, Burnette B, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest, 2014,124(2):687–695
[148]	Bertrand F, Montfort A, Marcheteau E, et al. TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma. Nat Commun, 2017,8(1):2256
[149]	Hodi FS, Lee S, McDermott DF, et al. Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. JAMA, 2014,312(17):1744–1753
[150]	Martinez M, Ono N, Planutiene M, et al. Granulocyte-macrophage stimulating factor (GM-CSF) increases circulating dendritic cells but does not abrogate suppression of adaptive cellular immunity in patients with metastatic colorectal cancer receiving chemotherapy. Cancer Cell Int, 2012,12(1):2
[151]	Ferrucci PF, Pala L, Conforti F, et al. Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma. Cancers (Basel), 2021,13(6):1383
[152]	Maung K, Nemunaitis J, Cunningham C. Granulocyte macrophage colony-stimulating factor (GM-CSF) genetransduced tumor vaccines (GVAX) in non-small-cell lung cancer. Clin Lung Cancer, 2001,3(1):25–26
[153]	Atallah-Yunes SA, Robertson MJ. Cytokine Based Immunotherapy for Cancer and Lymphoma: Biology, Challenges and Future Perspectives. Front Immunol, 2022,13:872010
[154]	Uricoli B, Birnbaum LA, Do P, et al. Engineered Cytokines for Cancer and Autoimmune Disease Immunotherapy. Adv Healthc Mater, 2021,10(15):e2002214
[155]	Li CY, Huang Q, Kung HF. Cytokine and immunogene therapy for solid tumors. Cell Mol Immunol, 2005,2(2):81–91
[156]	Nanni P, Forni G, Lollini PL. Cytokine gene therapy: hopes and pitfalls. Ann Oncol, 1999,10(3):261–266
[157]	Liu Y, Adu-Berchie K, Brockman JM, et al. Cytokine conjugation to enhance T cell therapy. Proc Natl Acad Sci U S A, 2023,120(1):e2213222120
[158]	Cheung NK, Kushner BH, Kramer K. Monoclonal antibody-based therapy of neuroblastoma. Hematol Oncol Clin North Am, 2001,15(5):853–866
[159]	Vornholz L, Isay SE, Kurgyis Z, et al. Synthetic enforcement of STING signaling in cancer cells appropriates the immune microenvironment for checkpoint inhibitor therapy. Sci Adv, 2023,9(11):eadd8564